EUVIMEDEUVIMED entdecken
Crossref

Chiral Iridium-Based TLD-1433 Analogues: Exploration of Enantiomer-Dependent Behavior in Photodynamic Cancer Therapy

Wen Wang, Lei Wang, Yangming Zhang, Yusheng Shi, Rong Zhang, Liyong Chen, Zhuolin Shi, Shuai Yuan, Xiaoxi Li, Cheng He iD, Xuezhao Li iD

Inorganic Chemistry · 2024

DOI: 10.1021/acs.inorgchem.4c00215 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inorganic Chemistry, 2024. Verfasst von Wen Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Hospital of Dalian University of Technology, School of Chemistry, State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dal…. Hauptthemen laut MEDLINE: Photochemotherapy, Iridium, Photosensitizing Agents, Antineoplastic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Anhui Province Key Laboratory of Translational Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metallodrug-based photodynamic therapy (PDT) agents have demonstrated significant superiority against cancers, while their different chirality-induced biological activities remain largely unexplored. In this work, we successfully developed a pair of enantiopure mononuclear Ir(III)-based TLD-1433 analogues, Δ-Ir-3T and Λ-Ir-3T, and their enantiomer-dependent anticancer behaviors were investigated. Photophysical measurements revealed that they display high photostability and chemical stability, strong absorption at 400 nm with high molar extinction coefficients (ε = 5.03 × 104 M-1 cm-1), and good 1O2 relative quantum yields (ΦΔ ≈ 47%). Δ- and Λ-Ir-3T showed potent efficacy against MCF-7 cancer cells, with a photocytotoxicity index of ≤44 238. This impressive result, to the best of our knowledge, represents the highest value among reported mononuclear Ir(III)-based PDT agents. Remarkably, Λ-Ir-3T tended to be more potent than Δ-Ir-3T when tested against SK-MEL-28, HepG2, and LO2 cells, with consistent results across multiple test repetitions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhotochemotherapyIridiumPhotosensitizing AgentsAntineoplastic AgentsDrug Screening Assays, AntitumorHumansStereoisomerismMolecular StructureCell ProliferationCell SurvivalCell Line, TumorCoordination Complexes

Substanzen

IridiumPhotosensitizing AgentsAntineoplastic AgentsCoordination Complexes

Autor:innen und Institutionen

  • Cancer Hospital of Dalian University of Technology, School of Chemistry, State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian 116024, China.
  • State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian 116024, China.
  • Anhui Province Key Laboratory of Cancer Translational Medicine, Bengbu Medical University, Bengbu, Anhui 233030, China.
  • Central Laboratory, Liaoning Cancer Hospital & Institute, Cancer Hospital of Dalian University of Technology, No. 44 Xiaoheyan Road, Dadong District, Shenyang 110042, China.

ORCID-Profile: Cheng He, Xuezhao Li

Förderung

  • National Natural Science Foundation of China
  • Anhui Province Key Laboratory of Translational Cancer Research

Zitieren

APA

Wang, W., Wang, L., Zhang, Y., Shi, Y., Zhang, R., Chen, L., Shi, Z., Yuan, S., Li, X., He, C., & Li, X. (2024). Chiral Iridium-Based TLD-1433 Analogues: Exploration of Enantiomer-Dependent Behavior in Photodynamic Cancer Therapy. Inorganic Chemistry. https://doi.org/10.1021/acs.inorgchem.4c00215

Vancouver

Wang W, Wang L, Zhang Y, Shi Y, Zhang R, Chen L, et al. Chiral Iridium-Based TLD-1433 Analogues: Exploration of Enantiomer-Dependent Behavior in Photodynamic Cancer Therapy. Inorganic Chemistry. 2024. doi:10.1021/acs.inorgchem.4c00215

BibTeX
@article{Wang2024,
  author = {Wang, Wen and Wang, Lei and Zhang, Yangming and Shi, Yusheng and Zhang, Rong and Chen, Liyong and Shi, Zhuolin and Yuan, Shuai and Li, Xiaoxi and He, Cheng and Li, Xuezhao},
  title = {Chiral Iridium-Based TLD-1433 Analogues: Exploration of Enantiomer-Dependent Behavior in Photodynamic Cancer Therapy},
  journal = {Inorganic Chemistry},
  year = {2024},
  doi = {10.1021/acs.inorgchem.4c00215}
}
Kostenlos starten →